 |
| |
|
Ç÷çÅæÁ¡¾È¾×(Ç÷ç¿À·Î¸ÞÅç·Ð) 6mL
|
|
Àü¹®ÀǾàǰ | ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
 |
Á¦Ç°º° ÀӺαݱ⠰í½Ã |
|
|
|
1µî±Þ: ¿øÄ¢Àû »ç¿ë±Ý±â / 2µî±Þ: ¸íÈ®ÇÑ ÀÓ»óÀû ±Ù°Å ¶Ç´Â »çÀ¯°¡ ÀÖ´Â °æ¿ì ºÎµæÀÌÇÏ°Ô »ç¿ë / Mµî±Þ: ÀÓ»óÀû»óȲ¿¡ µû¶ó 1µî±Þ ¶Ç´Â 2µî±ÞÀ¸·Î ºÐ·ùµÇ´Â ¼ººÐ
| ¼ººÐ¸í |
¼ººÐÄÚµå |
±Ý±âµî±Þ |
°í½Ã¹øÈ£ |
°í½ÃÀÏÀÚ |
ºñ°í |
| Fluorometholone |
161238COS |
2 |
20200130 |
20201228 |
(Á¡¾ÈÁ¦) ½ºÅ×·ÎÀ̵å Á¦Á¦ÀÇ ÃÖ±âÇü¼º À§Ç輺 |
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645104201
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\2,100 ¿ø/6mL/º´(2016.01.01)(ÇöÀç¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¿¯Àº À¯¹é»öÀÇ ¼ö¼º ÇöŹ¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 6¹Ð¸®¸®ÅÍ |
1 Á¡¾È¾× |
º´ |
8806451042000 |
8806451042017 |
|
|
| ÁÖ¼ººÐÄÚµå |
161238COS
[µ¿ÀÏÇÑ ÁÖ¼ººÐÄڵ带 °¡Áø ¿À¸®Áö³¯ ¶Ç´Â Á¦³×¸¯ ÀǾàǰ Á¶È¸]
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
¿Ü¾ÈºÎ ¹× Àü¾ÈºÎÀÇ ¿°Áõ¼º Áúȯ(¾È°Ë¿°, °á¸·¿°, °¢¸·¿°, °ø¸·¿°, »ó°ø¸·¿°, ȫä¿°, ȫä¸ð¾çü¿°, Æ÷µµ¸·¿°, ¼ö¼úÈÄ ¿°Áõ µî)
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
1ȸ 1~2¹æ¿ï, 1ÀÏ 2~4ȸ Á¡¾ÈÇÑ´Ù. Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
Á¡¾È ÈÄ ³²Àº ¾×°ú ¿ë±â´Â ¹Ù·Î ¹ö¸°´Ù. (1ȸ¿ë¿¡ ÇÑÇÔ)
|
| ±Ý±â |
1) Ç¥À缺 ´Ü¼øÆ÷Áø °¢¸·¿°(¼öÁö»ó °¢¸·¿°), ¿ìµÎ, ¼öµÎ¸¦ Æ÷ÇÔÇÑ ¹ÙÀÌ·¯½º¼º °¢,°á¸· Áúȯ ȯÀÚ
2) Áø±Õ¼º ¾ÈÁúȯ ȯÀÚ
3) ´«ÀÇ ¹ÌÄÚ¹ÚÅ׸®¾Æ °¨¿° ȯÀÚ
4) ¸¸¼º ¾È°Ë¿° ȯÀÚ
5) ÀÌ ¾à¿¡ °ú¹ÎÁõÀÇ º´·ÂÀÌ Àִ ȯÀÚ
|
| ½ÅÁßÅõ¿© |
1) °¢¸· »óÇÇ ¹Ú¸® ¶Ç´Â °¢¸· ±Ë¾ç ȯÀÚ(ÀÌ·¯ÇÑ Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ°í ¶ÇÇÑ °¢¸·Ãµ°øÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
2) °áÇÙ¼º ¾ÈÁúȯ, È³ó¼º ¾ÈÁúȯ ȯÀÚ(ÀÌ·¯ÇÑ Áõ»óÀÌ ¾Ç鵃 ¼ö ÀÖ°í ¶ÇÇÑ °¢¸·Ãµ°øÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.)
3) ³ì³»Àå ȯÀÚ
4) 2¼¼ ¹Ì¸¸ÀÇ ¿µ¾Æ
|
| ÀÌ»ó¹ÝÀÀ |
1) ´«
¨ç ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ Àå±â¿¬¿ë¿¡ ÀÇÇØ ½Ã½Å°æ ¼Õ»ó, ½Ã·ÂÀúÇÏ ¹× ½Ã¾ß°á¼ÕÀ» µ¿¹ÝÇÏ´Â ³ì³»Àå°ú ¾È¾Ð»ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖÀ¸¹Ç·Î Á¤±âÀûÀ¸·Î ¾È¾Ð °Ë»ç¸¦ ÇÑ´Ù.
¨è °¢¸·Æ÷Áø, °¢¸·Áø±ÕÁõ, ³ì³ó±Õ°¨¿°Áõ µîÀ» À¯¹ßÇÒ ¼ö ÀÖÀ¸¹Ç·Î ÀÌ·¯ÇÑ °æ¿ì¿¡´Â ÀûÀýÇÑ Ã³Ä¡¸¦ ÇÑ´Ù.
¨é °¢¸·Æ÷Áø, °¢¸·±Ë¾ç ¶Ç´Â ¿Ü»ó µî¿¡ »ç¿ëÇÑ °æ¿ì¿¡´Â õ°øÀ» ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
¨ê Àå±â »ç¿ë¿¡ ÀÇÇØ µå¹°°Ô Èij¶ÇÏ ¹é³»ÀåÀÌ ³ªÅ¸³ª´Â ¼ö°¡ ÀÖ´Ù.
¨ë Àå±â »ç¿ë¿¡ ÀÇÇØ ¼÷Áָ鿪¹ÝÀÀÀÇ ¾ïÁ¦·Î ÀÌÂ÷ ¾È°¨¿°ÀÇ À§ÇèÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Ù.
¨ì Ä¡·áµÇÁö ¾ÊÀº ±Þ¼ºÀÇ È³ó¼º ¾È°¨¿°ÀÌ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵åÀÇ »ç¿ë¿¡ ÀÇÇØ ÀºÆóµÇ°Å³ª ¾Ç鵃 ¼ö ÀÖ´Ù.
¨í ±Þ¼º Æ÷µµ¸·¿°, °¢¸·¿°, °á¸·¿°, °¢¸·±Ë¾ç, »êµ¿, °á¸·ÃæÇ÷, Á¶Àý¸¶ºñ, ¾È°ËÇϼö µîÀÌ ÀϾ ¼ö ÀÖ´Ù.
2) â»ó Ä¡À¯ÀÇ Áö¿¬ : ¹é³»Àå ¼ö¼ú ÈÄ Ã¢»ó Ä¡À¯ÀÇ Áö¿¬À» ÀÏÀ¸Å°´Â ¼ö ÀÖÀ¸¸ç ¼öÆ÷ Çü¼ºÀ» Áõ°¡½Ãų ¼ö ÀÖ´Ù.
3) Çϼöü¤ýºÎ½ÅÇÇÁú°è ±â´É : Àå±â »ç¿ë¿¡ ÀÇÇØ Çϼöü¤ýºÎ½ÅÇÇÁú°è ±â´ÉÀÇ ¾ïÁ¦¸¦ ÀÏÀ¸Å³ ¼ö ÀÖ´Ù.
4) °ú¹ÎÁõ : °ú¹ÎÁõ»óÀÌ ³ªÅ¸³ª´Â °æ¿ì¿¡´Â Åõ¿©¸¦ ÁßÁöÇÑ´Ù.
5) ÷°¡Á¦ : ÀÌ ¾àÀº Àλ꿰À» Æ÷ÇÔÇϰí ÀÖ´Ù.
»ó´çÇÑ °¢¸· ¼Õ»óÀÌ ÀÖ´Â ÀϺΠȯÀÚ¿¡¼ Àλ꿰 ÇÔÀ¯ Á¡¾È¾×ÀÇ »ç¿ë°ú ¿¬°üµÇ¾î °¢¸· ¼®È¸ÈÀÇ »ç·Ê°¡ ¸Å¿ì µå¹°°Ô(0.01% ¹Ì¸¸) º¸°íµÈ ¹Ù ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
1) CYP3A4 ÀúÇØÁ¦ (¸®Å䳪ºñ¸£ ¶Ç´Â ÄÚºñ½Ã½º ŸƮ Æ÷ÇÔ)¿Í º´¿ë Åõ¿©½Ã Àü½Å ³ëÃâÀÌ Áõ°¡µÇ¾î, Àü½ÅÀû ÀÌ»ó ¹ÝÀÀ ¹ß»ý À§ÇèÀÌ Áõ°¡ÇÒ ¼ö ÀÖ´Ù. Ä¡·á»óÀÇ À¯ÀͼºÀÌ Àü½Å ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å ÀÌ»ó¹ÝÀÀ ¹ß»ýÀÇ À§Ç輺À» »óȸÇÑ´Ù°í ÆÇ´ÜµÇ´Â °æ¿ì¿¡¸¸ º´¿ë Åõ¿©Çϸç, ȯÀÚÀÇ Àü½Å ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ¿µÇâÀ» »ìÆì¾ß ÇÑ´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: FLUOROMETHOLONEFLAREX (FLUOROMETHOLONE ACETATE)
FLUOR-OP (FLUOROMETHOLONE)
FML (FLUOROMETHOLONE)
FML FORTE (FLUOROMETHOLONE)
FML-S (FLUOROMETHOLONE; SULFACETAMIDE SODIUM)
OXYLONE (FLUOROMETHOLONE)
TOBRASONE (FLUOROMETHOLONE ACETATE; TOBRAMYCIN)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Ãà¾àº¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
(fluorometholone opthalmic )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| Á¦Çüº° º¹¾àÁöµµ |
[Á¡¾È¾×] |
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Fluorometholone¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
|
| Pharmacology |
Fluorometholone¿¡ ´ëÇÑ Pharmacology Á¤º¸ Corticosteroids such as fluorometholone inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.
|
| Metabolism |
Fluorometholone¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 3A4 (CYP3A4)
|
| Protein Binding |
Fluorometholone¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Fluorometholone¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Fluorometholone¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
FluorometholoneÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö : ´ëºÎºÐÀº ¹æ¼ö(aqueous humor)·Î Èí¼öµÇ°í ¼Ò·®ÀÌ Àü½ÅÈí¼ö µÈ´Ù.
|
| Biotransformation |
Fluorometholone¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Fluorometholone¿¡ ´ëÇÑ Toxicity Á¤º¸ Side effects may include acute anterior uveitis and perforation of the globe. Keratitis, conjunctivitis, corneal ulcers, mydriasis, conjunctival hyperemia, loss of accommodation and ptosis have occasionally been reported following local use of corticosteroids. LD50 = 234 mg/kg (rats)
|
| Drug Interactions |
Fluorometholone¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Fluorometholone¿¡ ´ëÇÑ Description Á¤º¸ A glucocorticoid employed, usually as eye drops, in the treatment of allergic and inflammatory conditions of the eye. It has also been used topically in the treatment of various skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p732)
|
| Dosage Form |
Fluorometholone¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Solution / drops OphthalmicSuspension Ophthalmic
|
| Drug Category |
Fluorometholone¿¡ ´ëÇÑ Drug_Category Á¤º¸ Anti-Allergic AgentsAnti-inflammatory AgentsGlucocorticoids
|
| Smiles String Canonical |
Fluorometholone¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1CC2C3CCC(O)(C(C)=O)C3(C)CC(O)C2(F)C2(C)C=CC(=O)C=C12
|
| Smiles String Isomeric |
Fluorometholone¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(C)=O)[C@@]3(C)C[C@H](O)[C@]2(F)[C@@]2(C)C=CC(=O)C=C12
|
| InChI Identifier |
Fluorometholone¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C22H29FO4/c1-12-9-17-15-6-8-21(27,13(2)24)20(15,4)11-18(26)22(17,23)19(3)7-5-14(25)10-16(12)19/h5,7,10,12,15,17-18,26-27H,6,8-9,11H2,1-4H3/t12-,15-,17-,18-,19-,20-,21-,22-/m0/s1
|
| Chemical IUPAC Name |
Fluorometholone¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (6S,8S,9R,10S,11S,13S,14S,17R)-17-acetyl-9-fluoro-11,17-dihydroxy-6,10,13-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-3-one
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2023-03-11
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|